moneyheap
LABD · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Direxion Daily S&P Biotech Bear 3X ETF (LABD) stock moving?
No news items or SEC filings were found for LABD in the review window, so this view rests only on the 30-day price and volume data. LABD closed at $6.82 on Nov 10, about 10.5% below the $7.62 close on Oct 22 and well below the $7.96 close on Oct 23. The sharpest recent move was a 9.1% drop on Nov 9 to $6.58 on 17.0M shares, followed by a 3.6% rebound on Nov 10 on lower volume of 12.3M. The Nov 5 session closed at $7.83 on 49.0M shares, the heaviest volume in the period, roughly double the typical 20-25M. Recent lows cluster near $6.43-6.51 (Oct 29, Nov 4 and Nov 9), and closes near $7.8-8.0 have acted as a ceiling. As a 3x inverse fund that resets daily, LABD's value moves against the S&P Biotech index and can drift over longer holding periods, so the lack of catalysts leaves the outlook close to neutral.
About Direxion Daily S&P Biotech Bear 3X ETF
LABD is a Direxion fund, launched in May 2015, that tries to return three times the opposite (-300%) of the S&P Biotechnology Select Industry Index's move each day. It's a short-term trading tool for betting against biotech stocks or hedging them. The leverage resets every day, so returns over longer periods can be very different from -3x the index's return.
How the fund works
The fund doesn't own biotech stocks. It gets its inverse exposure mostly through swap contracts and holds cash or Treasuries as collateral. It resets its leverage every day. Because of that daily reset, losses tend to build up over time when the market is choppy or rising, and the fund has lost most of its value over long periods: roughly -55% a year on average since launch, according to Direxion. The net expense ratio is about 1.07%. Its distributions, which are paid quarterly, come mainly from interest on its collateral. Reverse stock splits have happened in the past.
What usually moves LABD
- Daily moves in small- and mid-cap biotech stocks (the index weights companies roughly equally)
- Interest-rate expectations, since biotech stocks are very rate-sensitive
- FDA drug approvals and clinical-trial results
- Biotech mergers and acquisitions and the market for new stock listings (IPOs)
- Market swings that erode returns because of the daily leverage reset